miRNAs as Theragnostic Markers for PARP Inhibitor Resistance in Breast Cancer: A Systematic Review.

IF 3.5 4区医学 Q3 ONCOLOGY

Current cancer drug targets Pub Date : 2026-03-27 DOI:10.2174/0115680096450856260219065705

Mehran Molavand, Asal Golchin, Bahman Yousefi

{"title":"miRNAs as Theragnostic Markers for PARP Inhibitor Resistance in Breast Cancer: A Systematic Review.","authors":"Mehran Molavand, Asal Golchin, Bahman Yousefi","doi":"10.2174/0115680096450856260219065705","DOIUrl":null,"url":null,"abstract":"Introduction: This systematic review aims to evaluate the potential of mi-croRNAs (miRNAs) as theragnostic biomarkers for predicting resistance to PARP inhibitors in Breast Cancer (BC), highlighting their potential for personalized treatment strategies.Methods: Following PRISMA guidelines, we conducted a search in Scopus, EMBASE, Pub-Med, and Web of Science to identify studies on miRNAs as biomarkers for predicting PARP inhibitor response in BC. Articles were selected based on inclusion and exclusion criteria, focusing on in vitro and in vivo studies, with quality assessed using the SYRCLE tool and a customized checklist.Results: Seventeen studies were included, identifying 15 miRNAs with different expression patterns. Two main types of miRNA interactions with PARP inhibitors were observed: syn-ergistic and antagonistic effects, mediated through signaling pathway regulation and induc-tion of a BRCAness phenotype in DNA repair mechanisms.Discussion: The dual role of miRNAs in modulating PARP inhibitor response in BC is evi-dent. Several miRNAs, such as miR-451, miR-199a-3p, and miR-182, enhance PARP inhib-itor efficacy by targeting pathways like PI3K, BRCA1, and C/EBPβ. On the other hand, miR-181a and miR-214-5p contribute to resistance by upregulating STING and downregu-lating RAD51, respectively. These findings emphasize the complex role of miRNAs in ther-apy, highlighting their potential as both biomarkers and therapeutic targets in overcoming resistance.Conclusion: miRNAs are crucial in BC treatment with PARP inhibitors. Further clinical studies are needed to validate their roles and develop miRNA-based strategies to overcome PARP inhibitor resistance.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096450856260219065705","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This systematic review aims to evaluate the potential of mi-croRNAs (miRNAs) as theragnostic biomarkers for predicting resistance to PARP inhibitors in Breast Cancer (BC), highlighting their potential for personalized treatment strategies.

Methods: Following PRISMA guidelines, we conducted a search in Scopus, EMBASE, Pub-Med, and Web of Science to identify studies on miRNAs as biomarkers for predicting PARP inhibitor response in BC. Articles were selected based on inclusion and exclusion criteria, focusing on in vitro and in vivo studies, with quality assessed using the SYRCLE tool and a customized checklist.

Results: Seventeen studies were included, identifying 15 miRNAs with different expression patterns. Two main types of miRNA interactions with PARP inhibitors were observed: syn-ergistic and antagonistic effects, mediated through signaling pathway regulation and induc-tion of a BRCAness phenotype in DNA repair mechanisms.

Discussion: The dual role of miRNAs in modulating PARP inhibitor response in BC is evi-dent. Several miRNAs, such as miR-451, miR-199a-3p, and miR-182, enhance PARP inhib-itor efficacy by targeting pathways like PI3K, BRCA1, and C/EBPβ. On the other hand, miR-181a and miR-214-5p contribute to resistance by upregulating STING and downregu-lating RAD51, respectively. These findings emphasize the complex role of miRNAs in ther-apy, highlighting their potential as both biomarkers and therapeutic targets in overcoming resistance.

Conclusion: miRNAs are crucial in BC treatment with PARP inhibitors. Further clinical studies are needed to validate their roles and develop miRNA-based strategies to overcome PARP inhibitor resistance.

查看原文本刊更多论文

mirna作为乳腺癌PARP抑制剂耐药的诊断标志物：系统综述

本系统综述旨在评估micrornas （miRNAs）作为预测乳腺癌（BC）对PARP抑制剂耐药的诊断生物标志物的潜力，强调其个性化治疗策略的潜力。方法：遵循PRISMA指南，我们在Scopus， EMBASE， Pub-Med和Web of Science中进行了检索，以确定mirna作为预测BC中PARP抑制剂反应的生物标志物的研究。根据纳入和排除标准选择文章，重点关注体外和体内研究，使用sycle工具和定制的检查表评估质量。结果：纳入17项研究，鉴定出15种不同表达模式的mirna。研究人员观察到两种主要类型的miRNA与PARP抑制剂的相互作用：协同作用和拮抗作用，通过信号通路调节介导，并在DNA修复机制中诱导BRCAness表型。讨论：mirna在BC中调节PARP抑制剂反应的双重作用是显而易见的。几种mirna，如miR-451、miR-199a-3p和miR-182，通过靶向PI3K、BRCA1和C/EBPβ等通路来增强PARP抑制剂的功效。另一方面，miR-181a和miR-214-5p分别通过上调STING和下调RAD51参与抗性。这些发现强调了mirna在治疗中的复杂作用，强调了它们作为克服耐药性的生物标志物和治疗靶点的潜力。结论：mirna在PARP抑制剂治疗BC中起关键作用。需要进一步的临床研究来验证它们的作用，并开发基于mirna的策略来克服PARP抑制剂的耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.